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T
 
helper cell 1 (Th1)-dependent delayed hypersensitivity
reactions are an important part of host defenses against
intracellular infections. Yet, more than two centuries after
Jenner’s successful inoculation against smallpox, we still do
not know exactly how to produce safe vaccines that stimu-
late Th1 immunity. Specialized bone marrow–derived an-
tigen-presenting cells normally are required to initiate all T
cell–dependent immune responses (1). However, in order
for Th responses to shift to a Th1 phenotype, interleukin
(IL)-12 needs to be present at the time of antigen recogni-
tion (2). IL-12 drives natural killer (NK) and Th1 cells to
generate interferon (IFN)-
 
g
 
, that subsequently impels mac-
rophages to initiate delayed hypersensitivity reactions. IFN-
 
g
 
also inhibits the synthesis of IL-4 and IL-5 by Th2 cells (3).
In the absence of IL-12 induced IFN-
 
g
 
 production, Th2
responses usually dominate.
But how do particular infectious agents induce IL-12 re-
lease? Accumulating evidence indicates that immunostimu-
latory CpG sequences (ISS) in the DNA of bacteria may
be one of the major IL-12–inducing factors (4). Complete
Freund’s adjuvant, composed of killed mycobacteria dis-
persed in mineral oil, is an established inducer of Th1-
dependent delayed hypersensitivity reactions. More than 10
years ago, Tokunaga and coworkers discovered that DNA
purified from mycobacteria fostered the release of IFN-
 
g
 
by mouse NK cells (5). Fractionation of the DNA led to
the isolation of several different short palindromic se-
quences,  most of them centered around a CpG dinucleotide
core, that had direct NK stimulatory activity (6). Subse-
quent studies showed that synthetic phosphodiester or
phosphothioate oligodeoxynucleotides, which reproduced
the immunostimulatory DNA sequences from mycobacte-
ria, could activate NK cells and induce B lymphocyte pro-
liferation in vitro (6–9). Methylation of cytosine residues in
the bacterial DNA or in the corresponding oligodeoxynu-
cleotides destroyed their immunostimulatory activities (7).
During early investigations of DNA vaccination, we ob-
served that nonspecific bacterial DNA enhanced immune
responses to a coinjected antigen expression vector (10).
Naked DNA immunization stimulated a selective Th1 im-
mune response that persisted upon secondary challenge
with protein antigen (11). In some instances, the Th1
skewing effects of gene vaccines could be manipulated by
changing the number of immunostimulatory sequences in
the plasmid DNA backbone (12). Simple coinjection of
bacterial DNA or immunostimulatory oligodeoxynucle-
otides with a DNA vaccine or with representative protein
antigens also promoted antigen-specific Th1 responses (13,
14), even in mice with preexistent Th2 immunity. Incuba-
tion of purified human macrophages with bacterial DNA,
or with immunostimulatory CpG oligodeoxynucleotides,
stimulated the production of IL-12, IL-18, and IFN-
 
a
 
 (14).
Now, Chu et al. have shown that vaccination of mice
with an antigen and an immunostimulatory CpG oligode-
oxynucleotide in incomplete Freund’s adjuvant induced a
powerful Th1 immune response, comparable to that achieved
by coinjection of the antigen in complete Freund’s adju-
vant (15). In contrast, mice vaccinated with antigen and
control oligodeoxynucleotides lacking the CpG motif, de-
veloped a skewed Th2 type immune response.
An efficacious vaccine must be devoid of systemic toxic-
ity. Systemically administered immunostimulatory oligode-
oxynucleotides can trigger a cytokine syndrome in mice,
characterized by TNF release, hypotension, and shock (16).
Although exogenous IL-12 induces potent Th1 immune
responses, high concentrations of the cytokine also can be
harmful to the recipient (17). The potential side effects of
immunostimulatory CpG sequences could be reduced by
including them in the backbones of DNA vaccines, or by
tethering the immunostimulatory oligodeoxynucleotides di-
rectly to precipitated antigens.
We still do not understand how mouse macrophages, B
lymphocytes, and NK cells recognize specific DNA se-
quences in bacterial DNA. The immunostimulatory CpG
motifs could theoretically bind to complementary sequences
in DNA or mRNA. More likely, the unmethylated CpG
core interacts with one or more signal transduction mole-
cules in the cytoplasm, or on the plasma membrane. An
analogous system mediates the induction of IFN-
 
a
 
 synthe-
sis by double stranded viral RNA (18).
In the future, it may be possible to skew the immune re-
sponse to vaccination to a Th1, Th2, or a mixed Th1/Th2
outcome, simply by titering the concentrations of coad-
ministered immunostimulatory CpG oligodeoxynucleotides.
Th1 vaccines should be particularly useful for the preven-
tion and treatment of allergic diseases and asthma, since the
IFN-
 
g
 
 released by Th1 lymphocytes and NK cells can down-
regulate IgE synthesis, as well as inhibit Th2 cells that con-
trol the late phase component of the allergic response. It is
conceivable that the coadministration of an immunostimu-
latory oligodeoxynucleotide sequence with a weak tumor
antigen could stimulate a delayed hypersensitivity response
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sufficient to eliminate malignant cells. By increasing endog-
enous IFN-
 
g
 
 synthesis, therapeutic Th1 vaccines could pro-
mote recovery from chronic viral or parasitic infections.
In summary, immunostimulatory oligonucleotides are
adjuvants that simplify Th1 induction in experimental sys-
tems. Their applications in clinical immunology will de-
pend on whether the data generated in murine models will
be reproducible in humans and whether the side effects of
cytokine overproduction will be acceptable.
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